Regulated Cell Death Part B: Necroptotic, Autophagic and Other Non-Apoptotic Mechanisms (Methods in Enzymology): Volume 545

Name: Regulated Cell Death Part B: Necroptotic, Autophagic and Other Non-Apoptotic Mechanisms (Methods in Enzymology): Volume 545
Author: Avi Ashkenazi, Jim Wells, Junying Yuan
ISBN: 9780128014301

Avi Ashkenazi, Jim Wells, Junying Yuan

Language: English

Published by Academic Press 2014-08-01, 2014

012801430X / 9780128014301

Series: Book 183 of 272 - ISSN

Hardcover
New

See all details

Seller: Chiron Media, Wallingford, United KingdomChiron Media

5-star seller

AbeBooks seller since August 2, 2010

View this seller's items

Hardcover

Condition: New

£ 136.22

£ 15.49 shipping

Ships from United Kingdom to U.S.A.

Quantity: Over 20 available

Add to basket

Save for laterCreate a Want for similar items

Seller Inventory # 6666-ELS-9780128014301

Contact seller about this item

Report this item

Title: Regulated Cell Death Part B: Necroptotic, Autophagic and Other Non-Apoptotic Mechanisms (Methods in Enzymology): Volume 545
Author: Avi Ashkenazi, Jim Wells, Junying Yuan
Publisher: Academic Press 2014-08-01
Publication year: 2014
Condition: New
Binding: Hardcover
Language: English
ISBN 10: 012801430X
ISBN 13: 9780128014301
Series: Book 183 of 272: ISSN

About the Author

Dr Avi Ashkenazi received his PhD in Biochemistry in 1986 from the Hebrew University of Jerusalem, Israel. From 1986 to 1989 he trained as a postdoctoral fellow at the University of California, San Francisco, and the biotechnology company, Genentech. As a postdoc, he helped identify the muscarinic acetylcholine receptor gene family and deciphered its interactions with specific G proteins – work that in 1988 earned him and two of his colleagues the first prize of the Boehringer Ingelheim Award. In 1989 Dr Ashkenazi joined Genentech as s Scientist and progressed through the ranks to become Senior Staff Scientist and Director, most recently within the Research Oncology division. In the early 1990’s he contributed to the development and translation of a technology to fuse immunoglobulin Fc domains to other proteins, now used in numerous research laboratories and in important biotechnology drugs including Enbrel® and Eylea®. Subsequently, Dr Ashkenazi’s laboratory discovered several novel members of the tumor necrosis factor (TNF) superfamily, most notably, the apoptosis-inducing ligand Apo2L/TRAIL and its “death and “decoy receptors. Dr Ashkenazi’s basic research has focused on the mechanisms of apoptosis signaling by death receptors, and his translational work in this area pioneered the clinical development of pro-apoptotic receptor agonists (PARAs) for cancer therapy. To date, Dr Ashkenazi has published 110 research papers and 31 review articles and has co-edited a book on antibody fusion proteins. His top 5 publications have been cited in sum over 11,000 times. His work on death receptors is highlighted in the textbook: “The biology of Cancer by Robert A. Weinberg. He has presented 99 lectures at scientific institutions and conferences and is a named inventor on 59 issued US patents. Dr Ashkenazi co-chaired the international TNF conference in 2007 and has served or serves on the editorial boards of Current Biology, Clinical Cancer Research, Nature Reviews Cancer, Journal of Biological Chemistry, Cancer Biology & Therapy, Cell Death & Differentiation and Molecular Cancer Therapy.

James A. Wells, PhD, focuses on development of enabling technologies for engineering proteins and for identifying small molecules to aid in drug discovery for challenging targets such as allosteric regulation and protein-protein interactions. He is interested in the discovery and design of small molecules and enzymes that trigger or modulate cellular processes in inflammation and cancer. Using small molecules and engineered proteins, the Wells lab is studying how activation of particular signaling nodes involving protease, kinases, or ubiquitin ligases drives cell biology. The lab has focused much on a set of proteases, known as caspases, responsible for fate determining cellular decisions involved in apoptosis and innate inflammation among others. These enzymes act as cellular remodelers and help us understand the essential protein struts that support life. These targets also provide leads for developing new cancer therapeutics and biomarkers for cancer treatment.

Wells is a professor and chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy. He holds a combined appointment as professor in the Department of Cellular & Molecular Pharmacology in the School of Medicine. He joined UCSF in 2005 as holder of the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences. Wells also founded and directs the Small Molecule Discovery Center (SMDC) located at UCSF’s Mission Bay campus. He earned a PhD degree in biochemistry from Washington State University with Professor Ralph Yount in 1979 and completed postdoctoral work at Stanford University School of Medicine with Professor George Stark in 1982. Before joining UCSF, Wells was a founding scientist in Genentech’s Protein Engineering Department and in 1998 co-founded Sunesis Pharmaceuticals.

Wells is a recipient of the Hans Neurath Award by the Protein Society, the Pfizer Award and Smissman Award given by the American Chemical Society, the Perlman Lecture Award given by the ACS Biotechnology Division, the du Vigneaud Award given by the American Peptide Society, the Merck Award from the ASBMB and in 1999 a member of the National Academy of Sciences.

"About the title" may belong to another edition of this title.

Chiron Media

Wallingford, United Kingdom

5-star seller

AbeBooks seller since August 2, 2010

Shipping rates from United Kingdom to U.S.A.

Item	14 to 21 business days	14 to 21 business days
First item	£ 15.49	£ 15.49

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.

Payment methods

Seller's business information

WRAP Ltd

Unit 4, 119 Loverock Rd
Reading, United Kingdom RG30 1DZ

Contact sellerView this seller's itemsView seller's storefront

Terms of sale

TBA

Right of withdrawal

If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.

Information regarding the right of withdrawal

Statutory right to withdraw

You have the right to withdraw from this contract within 14 days without giving any reason.

The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.

To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.

To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.

Effects of withdrawal

If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).

We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.

We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.

We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.

We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.

You shall send back the goods or hand them over to Chiron Media, Wallingford, United Kingdom, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.

Exceptions to the right of withdrawal

The right of withdrawal does not apply to:

The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.

Shipping terms

Shipping costs are based on books weighing 2.2 LB, or 1 KG. If your book order is heavy or oversized, we may contact you to let you know extra shipping is required.